SEPN to report oral PTH agonist Phase I data in Q1
SEPN is advancing an oral PTH receptor agonist for hypoparathyroidism, with full Phase I data expected in Q1 next year. The company is also expanding into Graves' disease, osteoporosis and mast cell diseases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.